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Abstract CCN proteins are key regulators of signaling
pathways that are essential for the control of normal life,
from birth to death. As such, they make use of their unique
mosaic structure to interact with several other regulatory
proteins and ligands that control the fate of living cells. The
various functions attributed to the CCN proteins may
sometimes appear contradictory, but this situation reflects
the complexity of the multimolecular scaffolds in which
CCN proteins are engaged and the critical impact of the
microenvironment that dictates the bioavailability of the
elementary building blocks. CCN3 is one of the best
examples of a CCN protein showing biological properties
which may at first glance appear opposite or contradictory.
Indeed, CCN3 acts both as a tumor suppressor and is
associated with higher metastatic potential. Furthermore,
the physical interaction of CCN3 with VEGF and its
potential antiangionenic activity in glioma cells are in
apparent contradiction with its proangiogenic activity in
rabbit cornea. In this communication, I am revisiting the
observations that led us to these apparent contradictions.
After pointing out how the methodologies that were
employed might have contributed to the confusion, I briefly
discuss the dual biological activities of CCN3 in the context
of tumor cell engineering and survival prognosis.
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Introduction
The CCN family of proteins contains six members
designated CCN1 through CCN6. All these proteins share
a common mosaic structure made up of the assembly of
four modules. These modules share partial identity with
four other large groups of regulatory proteins: IGF binding
proteins (IGFBP); von Willebrand factor (VWC); thrombo-
spondin type-1 (TSP1) and a group of growth factors and
matrix proteins that contain a cysteine knot (CT). For a
detailed review of the structural features of the CCN
proteins, see the recent review by Holbourn et al. (2008).
Apart from CCN5, which lacks a CT module, all CCN
proteins share a closely related primary structure which
includes a series of 38 cysteine residues that are strictly
conserved in position and number except in CCN6 which is
missing four cysteine residues in domain II (VWC;
Holbourn et al. 2008).
CCN proteins are key signaling molecules which act
both in the extracellular matrix, where they are secreted,
and inside cells, where they can be detected in the
cytoplasm and the nucleus. The pathways in which they
were found to play essential roles include: regulation of
adhesion, mitogenesis, migration and chemotaxis, cell
survival, differentiation, angiogenesis, chondrogenesis,
tumourigenesis and wound healing. They have also been
implicated in many human diseases [for some comprehen-
sive reviews see (Perbal 2001; Perbal and Takigawa 2005;
Leask and Abraham 2006].
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CCN3 is the first example of a CCN protein with
antiproliferative and tumor suppressor activities
The gene encoding CCN3 was originally identified in
myeloblastosis associated virus (MAV) - induced nephroblas-
toma in chickens (Joliot et al. 1992; Perbal 1994). These
avian tumors constitute a unique model of the Wilms’ tumor
in children (Perbal 1994) as they show all histological
features of the human counterpart.
In one tumor, the MAV proviral genome was integrated
into a cellular gene whose five exons encoded a putative
32 KDa protein in normal cells. The chimeric gene that
resulted from the insertion of MAVencoded large amounts of
an amino-truncated protein that proved to induce cellular
transformation when expressed in normal primary chicken
fibroblasts (CEF; Joliot et al. 1992). Interestingly, high levels
of the full length normal protein were also detected in other
MAV-induced nephroblastomas, hence the initial designa-
tions of this gene as nov (for nephroblastoma overexpressed)
and novH for the human gene (Perbal 2006a).
Because the expression of the recombinant full length
CCN3(NOV) protein induced growth arrest in CEF, the
high levels of CCN3 found in the tumors was raising an
apparent contradiction: how high levels of a protein with a
negative effect on cell growth could be detected in well-
developed aggressive avian tumors?
Our starting premise was that high levels of CCN3
matched the heterotypic differentiation of the blastemal
cells into cartilage, bone, and muscle tissues as observed in
these tumors (Chevalier et al. 1998). Indeed, we had
obtained evidence suggesting that CCN3 was associated
with growth arrest and differentiation of cartilage, bone and
muscle in normal conditions (Perbal 2001).
Evidence accumulated rapidly in favor of CCN3 acting
as antiproliferative and a tumor suppressor.
Glioma cells in which we forced the expression of CCN3
were growing at a much lower rate than their parental
counterpart (Gupta et al. 2001). The expression of CCN3
into these cells considerably reduced their ability to induce
tumors when injected into nude mice. Likewise, the ectopic
expression of CCN3 in Ewing’s cells reduced both their
growth and tumorigenicity (Lin et al. 2003) In fact, cells
engineered to produce CCN3 gave rise to abortive tumors
that eventually regressed (Lin et al. 2003)
We had proposed that CCN3 impaired the development
of the vasculature required for efficient development of the
explanted tumor cells and that CCN3 might be used as an
anti-cancer agent (Gupta et al. 2001).
The potential anti-angiogenic effect of CCN3 agrees
with evidence supporting a physical interaction between
CCN3 and VEGF (Perbal 2006b, and unpublished results),
but apparently contrasts with the observation that CCN3
induces neovascularization when implanted in rat cornea
(Lin et al. 2003).
In the case of chronic myeloid leukemia (CML), the
expression of CCN3 was high in patients who recovered
after treatment with imatinib, whereas it was considerably
reduced in patients in the acute phase of tumor develop-
ment and patients with relapse after drug treatment
(McCallum et al. 2006).
Recent results indicated that CCN3 can restore regula-
tory processes in CML cells by inhibiting proliferation and
inducing apoptosis (S. Irvine, personal communication). It
was previously reported that the expression of CCN3
resulted in a higher number of apoptotic cells in Ewing
tumor cell cultures (Benini et al. 2005). However, melano-
cytes transfected with an adenoviral construct driving the
expression of CCN3 were growth-inhibited but did not
show an increase of apoptosis, as measured by caspase 3
levels (Fukunaga-Kalabis et al. 2006). Therefore, these
observations suggested that the apoptotic effects of CCN3
might be cell type specific.
Interestingly, the expression of the cell cycle inhibitor
protein p21 was found to be increased in response to CCN
expression in gliomas (Bleau et al. 2007) in melanocytes
(Fukunaga-Kalabis et al. 2006) and Kusa cells (Katsuki et
al. 2008) reinforcing the idea that the antiproliferative
activity of CCN3 was independent of apoptosis.
Early analysis of CCN3 expression in renal cell
carcinoma (Glukhova et al. 2001) and prostate cancer cells
(Maillard et al. 2001) had led to the conclusion that an
elevated expression of CCN3 was associated with a high
proliferative rate for these tumor cells. In light of a report
that also associated high expression of CCN3 to active
cellular proliferation (Liu et al. 1999), an apparently
paradoxical situation developed.
However, the data that associated CCN3 to stimulation
of cell growth were based on the direct or indirect
measurement of cells in the S phase, not on cell counts.
Our recent results (Bleau et al. 2007) established that the
negative effect of CCN3 on cell growth resulted from a
“slow down” of the S-G2 transition with a relative
reduction in the number of cells undergoing a complete
cell cycle, and a temporary increase of cells in the S phase
(Fig. 1).
Given these results, the previous observations that
associated high CCN3 expression with increased cell
multiplication, in fact reflected the increase in the number
of cells in the S phase that resulted from the antiprolifer-
ative activity of CCN3.
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In conclusion, claims that CCN3 could stimulate or be
associated with increased cell proliferation were misguided
by our lack of knowledge regarding the biological effects of
CCN3 on the cell cycle.
Mr. Hyde
CCN3 expression is associated with metastatic potential
Despite its antiproliferative activity on tumor cells, CCN3
was also found to increase the migration and invasion of
Ewing’s tumor cells (Benini et al. 2005). Motility assays
performed using Transwell chambers with 8 μm pore size,
established that CCN3 expressing cells migrated three to
four times faster than the parental cells which did not
express detectable amounts of CCN3. Also, when invasion
capacity was assessed in Matrigel invasion assay, cells
expressing high levels of CCN3 migrated twice as much as
the parental cells (Benini et al. 2005).
These observations were consistent with the association
that we had previously established between CCN3 expres-
sion and worse patient outcome (Manara et al. 2002).
Indeed, the increase of mobility and invasion conferred by
CCN3 on the transfected cells accounted for the higher
metastatic potential of Ewing cells positive for CCN3 in the
primary tumor (Manara et al. 2002). More recently,
quantitative PCR measurement of CCN3 in patients
confirmed that the expression of CCN3 was associated
with poor prognosis (Perbal et al., submitted)
Similar conclusions were reached in the cases of
osteosarcomas. In these tumors, we could establish that,
not only was an elevated expression of CCN3 associated
with a higher risk of developing metastasis, it also matched
increased levels of MRD4 protein in these cells. While the
expression of CCN1 and CCN2 was correlated to the
expression of ostogenic differentiation markers, and
showed no prognostic value in osteosarcomas, the levels
of CCN3 in these tumors were independent of differentia-
tion markers expression (Perbal et al. 2008).
In the case of melanomas, CCN3 protein levels were
significantly higher in cells from stage IIIB-C patients with
short survival than in melanoma cells from patients with
long survival (Vallacchi et al. 2008). The role of CCN3 in
the establishment of visceral metastases was supported by
the observation that SCID mice injected with cells stably
expressing CCN3 developed a much higher number of
hepatic metastatic metastases than the mice injected with
CCN3 negative tumor cells (Vallacchi et al. 2008).
Discussion
The observations reported above clearly demonstrate the
need to clarify precisely the experimental conditions and
the biological systems used to assess the biological
properties of CCN proteins.
According to the literature, it is obvious that we must
distinguish between two fundamentally different situations
regarding the consequences of (1) forced expression (high
or low) of a CCN protein in a cell in which there is no
detectable production of that protein, and (2) endogenous
production of the same CCN protein.
In both cases, one can predict that, based on the
multimodular structure of the CCN proteins and their
ability to interact with several partners, the biological
properties of CCN proteins will depend upon the local
context; i.e., the bioavailability of the various partners at a
precise time and a precise location in the organism. This
aspect has already been discussed (Perbal 2001) and there is
an increasing body of evidence supporting that model.
On the contrary, so far not much has been done to
compare the biological properties of CCN proteins produced
endogenously with those of the same proteins produced by
genetic engineering. Along the same line, addition of a
particular recombinant CCN protein to cells that do not
produce it may result in biological effects that are distinct
from those which would result from the production of the
protein by these cells. Several reasons may account for these
potential differences. For example, it is quite conceivable
that the endogenous CCN proteins expressed naturally by
cells are modified, at a post-translational level, by these cells
and might combine to other chaperone or transporters that
may eventually affect their biological properties through
addressing or by favoring interactions with multiprotein
complexes at a higher organizational level.
There is no doubt that highly organized macromolecular
complexes must be the basis for efficient coordinated
signaling networks. How CCN proteins integrate such
complexes is a very timely and challenging question, since
answers that will be drawn from such studies will shed new
light on the biological properties of CCN proteins.
Fig. 1 Effect of CCN3 on cell cycle progression. The G59 glioma cells
(CCN3 negative) and their G540 transfected derivative (CCN3 positive)
were synchronized by release of an aphidocolin block. The distribution of
the growing cells in the four different phases of the cell cycle was
established by FACS analysis. See Bleau et al. (2007) for experimental
details
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Strategies aimed at stimulating or inhibiting expression
of CCN proteins in cells that do not produce them may be a
way to tackle these problems as long as the biological
systems in which we perform these manipulations are
compatible with the expression of CCN proteins. In other
words, expressing a CCN protein in a context where it is
not able to combine with its natural partners or where it will
physically interact with proteins that are not in its natural
environment in vivo, might lead to effects that are not
relevant to the biology of these proteins.
The numbers of conflicting observations that are
assigned to different “micro-environments”, or various
“biological contexts,” may in fact result from the different
experimental protocols that were used.
These two parameters are important, but they must be
considered in physiological situations.
Strategies based on the ectopic addition of recombinant
CCN proteins may also lead to misinterpretations, since
exogenous proteins may not be channeled properly to their
biological targets, either at the level of the cell membrane,
extracellular matrix, or inside the cells.
These considerations might help us understand why the
same CCN protein shows quite distinct properties, such as
the pro- and anti-angiogenic activity of CCN3, when added
exogenously or expressed from inside the cell. They can
also provide explanations for the dual biological properties
of CCN3 versus tumor cells.
As described above, the CCN3 protein shows growth
inhibitory and tumor suppressor functions, whereas expres-
sion of CCN3 is associated with higher risk of developing
metastases.
It is conceivable that the exogenous protein interacts
with outbound signaling pathways so as to reduce the
progression in the cell cycle, whereas production of CCN3
by tumor cells might affect the sub cellular distribution and
processing of CCN3. Along this line, the negative effects of
the secreted CCN3 protein would be counter-balanced by
the production and subcellular distribution of intracellular
CCN3 proteins that would interact with “inbound” signal-
ing pathways. Disturbance of these signaling pathways may
account, at least in part, for the association between CCN3
expression and bad prognosis
The detection of nuclear CCN proteins in tumor cells is
well-documented (Perbal 2004), and there is an increasing
body of evidence in favor of nuclear CCN proteins involved
in cell proliferation. In the case of CCN3, accumulation of
CCN3 in the nucleus of tumor cells (Perbal 1999) is believed
to repress the expression of tumor suppressor genes thereby
contributing to the loss of negative signals controlling
proliferation (Planque et al. 2006).
Understanding at a molecular level how the CCN
proteins become part of multimolecular regulatory com-
plexes and exert their functions in extra-cellular and intra-
cellular signaling is a main challenge that future studies will
need to address.
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